eye drop for the treatment of dry eye syndrome using the immunomodulator cyclosporine, also called restasis (Allergan)
90
Structured Review
Allergan
eye drop for the treatment of dry eye syndrome using the immunomodulator cyclosporine, also called restasis
Eye Drop For The Treatment Of Dry Eye Syndrome Using The Immunomodulator Cyclosporine, Also Called Restasis, supplied by Allergan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dry+eye+treatment+restasis/eye+drop+for+the+treatment+of+dry+eye+syndrome+using+the+immunomodulator+cyclosporine++also+called+restasis/us11712414-19-18-22
Average 90 stars, based on 1 article reviews
Eye Drop For The Treatment Of Dry Eye Syndrome Using The Immunomodulator Cyclosporine, Also Called Restasis, supplied by Allergan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dry+eye+treatment+restasis/eye+drop+for+the+treatment+of+dry+eye+syndrome+using+the+immunomodulator+cyclosporine++also+called+restasis/us11712414-19-18-22
Average 90 stars, based on 1 article reviews
eye drop for the treatment of dry eye syndrome using the immunomodulator cyclosporine, also called restasis - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Saint Regis Mohawk Tribe v. Mylan Pharm. Inc.United States Court of Appeals of the Federal Circuit, 2018896 F.3d 1322 Article Snippet: The story began when Allergan sued Abbreviated New Drug Application (ANDA) filers, alleging that their proposed generic products would infringe patents relating to Allergan’s drug Restasis, used for alleviating the symptoms of chronic dry eye.. The ANDA filers responded by filing numerous inter partes review (IPR) petitions challenging the Restasis patents.. In an attempt to shield the patents from IPR, Allergan entered into an agreement with the St. Regis Mohawk Tribe, pursuant to which the Restasis patents were assigned to the Tribe and the Tribe moved to terminate the IPRs, arguing that it is entitled to assert tribal sovereign immunity. |